Recursion Reports Q4 Revenue of $35.5M, Exceeding Expectations
Reports Q4 revenue $35.5M, consensus $24.56M. Cash, cash equivalents and restricted cash were $753.9M as of December 31, 2025 compared to $603.0M as of December 31, 2024. Based on current operating plans and with no additional financing, the Company's expected cash runway extends into early 2028. "Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value," said Najat Khan, CEO & President of Recursion. "Our first AI-enabled clinical proof of concept in FAP and our fifth program milestone achieved with Sanofi reflect the increasing maturity of a deeply integrated model - one that connects biology, chemistry, and clinical development into a continuous learning system. We enter 2026 with five differentiated clinical programs advancing with defined next-stage milestones, a growing discovery portfolio informed by proprietary platform insights, and more than $500M in upfront and progress-based milestone payments earned to date. Pairing bold ambition with disciplined execution, we are building Recursion to compound over time - translating insight into molecules, molecules into medicines, and innovation into measurable impact for patients and shareholders alike."
